NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Empire Genomics announced today that it has signed a distribution deal for its products in China with contract research organization HemaTone Beijing.
Growing demand in the region for cancer diagnostics was the impetus for the deal, which is expected to bring in more than $5 million in revenues for Empire over the five-year term of the agreement, the company said. HemaTone will distribute Empire's personalized diagnostic testing products in China, and will provide product training and marketing support to its clients.
Further financial terms were not disclosed.
"Finding a like-minded and experienced diagnostic partner such as HemaTone is crucial to our successful commercialization efforts in China," said Empire President and CEO Anthony Johnson in a statement. "Additional key requirements for us include deep Chinese regulatory knowledge and customer penetration. We chose HemaTone as our partner based on their strong track record of success with both of these attributes. We are excited to begin working with the HemaTone organization to bring the best in personalized medicine to the Chinese marketplace."